Iowa Lottery Action, Vol. 18, No. 15, July 25-Aug. 7, 2011

Iowa Lottery Retailer Newsletter

Time invested in the global respiratory care of cystic fibrosis paediatrics patients.

INTRODUCTION: Respiratory therapy is a keystone of the treatment for cystic fibrosis (CF) lung disease, but it is time consuming. OBJECTIVES: We aimed to assess the total time spent on respiratory therapy, including chest physiotherapy (CPT) and physical activity (PA), as well as inhalation therapy (IT) and maintenance of materials (MM) to rationalise and optimise treatment. METHODS: A cross-sectional prospective study in a paediatric CF cohort. A questionnaire was developed to look at the time spent on respiratory care over 3 months. Enrolled in this study are all CF patients aged from 6 to 16 years (the exclusion criterion was lung transplantation). RESULTS: Of the 40 enrolled patients, 22 participated (13 boys and 9 girls), with a mean age of 11 years. The patients spent approximately 19.46 h per week (standard deviation ± 7.53, 8.00-35.25 h) on therapy: CPT (30.58%), IT (15.11%), PA (50%) and MM (4.32%), without statistical significance between sexes. CONCLUSION: In our cohort, CF patients spent an average of nearly 20 h a week in respiratory therapy, within a wide range of between 8 h to almost 36 h a week. PA consumes almost half of the time. Physicians have to take into consideration the burden of the treatment, to optimise the therapy.

Lessons Learned from 15 Years of KIMS and 5 Years of ACROSTUDY.

Background: Pharmacoepidemiological surveys provide a valuable contribution to the continued monitoring of drug-related effects in patients with rare disorders. One of the earliest examples of this type of survey is KIGS (Pfizer International Growth Study Database), which has monitored the safety and effectiveness of growth hormone (GH) therapy in GH-deficient children since its inception in 1987. Following closely in the footsteps of KIGS is KIMS (Pfizer International Metabolic Database). As of 2009, KIMS has been collecting data on the long-term safety and clinical outcomes of GH replacement in GH-deficient adults for 15 years. Approximately 5 years ago, the ACROSTUDY database was established to monitor the long-term safety and effectiveness of pegvisomant in patients with acromegaly. Conclusions: By collecting data on the treatment of relatively rare conditions in routine clinical practice, pharmacoepidemiological surveys such as KIMS and ACROSTUDY provide valuable information on the safety and effectiveness of treatment with GH replacement and pegvisomant in the real world.

Iowa Animal Industry News, 2014, Vol. 15, no. 1

Newsletter produced by Department of Agriculture and Land Stewardship about the animal industry in Iowa. Previously titled Animal Industry News.

List of Bid Proposal Holders, April 15, 2014

List of Bid Proposal Holders

Ag Decision Maker, April 2011, Vol. 15, no. 6

A Business Newsletter for Agriculture

Ag Decision Maker, August 2011, Vol. 15, no. 10

A Business Newsletter for Agriculture

Ag Decision Maker, December 2010, Vol. 15, no. 2

A Business Newsletter for Agriculture

Report on a special investigation of the City of Kinross for the period January 15, 2008 through October 31, 2013

Report on a special investigation of the City of Kinross for the period January 15, 2008 through October 31, 2013

Ag Decision Maker, February 2011, Vol. 15, no. 4

A Business Newsletter for Agriculture

Ag Decision Maker, January 2011, Vol. 15, no. 3

A Business Newsletter for Agriculture

Ag Decision Maker, July 2011, Vol. 15, no. 9

A Business Newsletter for Agriculture

Ag Decision Maker, June 2011, Vol. 15, no. 8

A Business Newsletter for Agriculture